Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Dr. Reddy’s Laboratories Ltd. ADR’s stock clocked out at $13.88, up 1.61% from its previous closing price of $13.66. In other words, the price has increased by $1.61 from its previous closing price. On the day, 0.93 million shares were traded. RDY stock price reached its highest trading level at $13.92 during the session, while it also had its lowest trading level at $13.74.
Ratios:
To gain a deeper understanding of RDY’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 84.30. For the most recent quarter (mrq), Quick Ratio is recorded 1.35 and its Current Ratio is at 1.85. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.03.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RDY now has a Market Capitalization of 11609448448 and an Enterprise Value of 3875312896. As of this moment, Dr.’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.99, and their Forward P/E ratio for the next fiscal year is 22.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.90 while its Price-to-Book (P/B) ratio in mrq is 2.87. Its current Enterprise Value per Revenue stands at 0.011 whereas that against EBITDA is 0.044.
Stock Price History:
The Beta on a monthly basis for RDY is 0.39, which has changed by -0.029829562 over the last 52 weeks, in comparison to a change of 0.1177547 over the same period for the S&P500. Over the past 52 weeks, RDY has reached a high of $16.17, while it has fallen to a 52-week low of $12.26. The 50-Day Moving Average of the stock is -1.55%, while the 200-Day Moving Average is calculated to be -1.43%.
Shares Statistics:
It appears that RDY traded 1.01M shares on average per day over the past three months and 956310 shares per day over the past ten days. A total of 834.61M shares are outstanding, with a floating share count of 832.34M. Insiders hold about 0.00% of the company’s shares, while institutions hold 13.13% stake in the company. Shares short for RDY as of 1763078400 were 8051861 with a Short Ratio of 8.47, compared to 1760486400 on 8545110. Therefore, it implies a Short% of Shares Outstanding of 8051861 and a Short% of Float of 1.8800000000000001.
Dividends & Splits
With its trailing 12-month dividend rate of 8.0, RDY has a forward annual dividend rate of 0.09. Against a Trailing Annual Dividend Yield of 0.5856515. The stock’s 5-year Average Dividend Yield is 0.72. . The current Payout Ratio is 8.90% for RDY, which recently paid a dividend on 2025-07-25 with an ex-dividend date of 2025-07-25. Stock splits for the company last occurred on 2024-11-05 when the company split stock in a 5:1 ratio.
Earnings Estimates
Analysts are recommending an EPS of between $61.53 and $61.53 for the fiscal current year, implying an average EPS of $61.53. EPS for the following year is $56.62, with 1.0 analysts recommending between $56.62 and $56.62.
Revenue Estimates
In . The current quarter, 4 analysts expect revenue to total $84.67B. It ranges from a high estimate of $89.02B to a low estimate of $82.98B. As of . The current estimate, Dr. Reddy’s Laboratories Ltd. ADR’s year-ago sales were $83.59BFor the next quarter, 4 analysts are estimating revenue of $85.08B. There is a high estimate of $91.6B for the next quarter, whereas the lowest estimate is $79.24B.
A total of 38 analysts have provided revenue estimates for RDY’s current fiscal year. The highest revenue estimate was $372.71B, while the lowest revenue estimate was $325.18B, resulting in an average revenue estimate of $342.31B. In the same quarter a year ago, actual revenue was $325.54BBased on 37 analysts’ estimates, the company’s revenue will be $349.9B in the next fiscal year. The high estimate is $408.94B and the low estimate is $321.22B.
